GPP
OSIR

Great Point Partners’s Osiris Therapeutics, Inc. Common Stock OSIR Stock Holding History

Great Point Partners’s Portfolio OSIR Stock Details OSIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-75,000
Closed -$1.39M – 37
2015
Q3 		$1.39M Buy
+75,000
New +$1.45M 0.55% 30
2015
Q2 		– Sell
-12,165
Closed -$214K – 47
2015
Q1 		$214K Buy
+12,165
New +$204K 0.09% 32

Other funds holding OSIR

CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
QI
QS Investors New York $8.47B AUM 30.71% 1-Year Est. Return

Great Point Partners's OSIR Position: Q4 2015 in Review

Great Point Partners sold out of Osiris Therapeutics, Inc. Common Stock (OSIR) in Q4 2015, closing a stake of 75,000 shares — an estimated $1.39M sold.

Great Point Partners first reported a position in OSIR in Q1 2015 and held it in 2 quarters. The position peaked at $1.39M in Q3 2015. 81 funds tracked by Wall St. Rank hold OSIR as of Q4 2015.

  • Great Point Partners reported no remaining Osiris Therapeutics, Inc. Common Stock position as of Q4 2015 after selling out during the quarter.
  • Great Point Partners sold 75,000 Osiris Therapeutics, Inc. Common Stock shares in Q4 2015, an estimated $1.39M.
  • Great Point Partners first reported a position in Osiris Therapeutics, Inc. Common Stock in Q1 2015 and held it in 2 quarters.
  • Great Point Partners's Osiris Therapeutics, Inc. Common Stock position peaked at $1.39M in Q3 2015.
  • 81 funds tracked by Wall St. Rank held Osiris Therapeutics, Inc. Common Stock as of Q4 2015.

Based on Great Point Partners's 13F filing for Q4 2015, filed 16 Feb 2016.